Drug-Resistant Malaria - libdoc.who.int - World Health Organization
Drug-Resistant Malaria - libdoc.who.int - World Health Organization
Drug-Resistant Malaria - libdoc.who.int - World Health Organization
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
CONTENTS<br />
Page<br />
<strong>Drug</strong> Pressure and Resistance .......... .<br />
<strong>Drug</strong> Combinations and Synergism in Relation to the<br />
Prevention of the Development of <strong>Drug</strong> Resistance<br />
Exo-Erythrocytic Development of <strong>Malaria</strong> Parasites.<br />
Chloroquine Retinopathy .....<br />
Clinicl-ll Pharmacological Studies .•.......<br />
54<br />
55<br />
56<br />
56<br />
56<br />
VI.<br />
CONTROL OF DRUG-RESISTANT P.FALCIPARUM<br />
Control of Transmission and Prevalence<br />
<strong>Drug</strong> Use Aiming at Preventing, Delaying<br />
or Reversing the Selection of <strong>Resistant</strong><br />
P. falciparum •• ......•.••••...<br />
59<br />
59<br />
63<br />
VII.<br />
FIELD AND LABORATORY RESEARCH FOR THE CONTROL<br />
OF RESISTANT P.FALCIPARUM 75<br />
GENERAL TOPICS .<br />
SPECH'IC TOPICS<br />
PRIORITY TOPICS<br />
75<br />
76<br />
81<br />
VITI. RECOMMENDATIONS 85<br />
IX<br />
National and International Cooperaztion<br />
Parasite Genetics .......... .<br />
Evaluation and Development of Antimalarial <strong>Drug</strong>s<br />
Training<br />
SUMMARY<br />
86<br />
86<br />
87<br />
88<br />
91<br />
APPENDICES<br />
1. List of Participants, Observers<br />
and Secretariat . . . . • . . . 93<br />
2. List of Documents . . . . . . . . 103<br />
3. Response of P.falciparum to Chloroquine<br />
and Mefloq;:;T;;; . . . • . • • . . 107<br />
l~.<br />
Sample Size in Studies on <strong>Drug</strong> Response of<br />
Plasmod ium falc iparum . . . . . . III<br />
5. Antimalarial <strong>Drug</strong>s and <strong>Drug</strong> Regimens<br />
( F a 1 c i p a rum Ma 1 a r i a ) • • . . . . . 11 3<br />
6. Future Deployment of Mefloquine and Essentil-ll<br />
Measures for Protecting Mefloquine Against<br />
Resistance . . . . . . . . . • . . . . 123<br />
7. Outline Research Proposals. • • . . • . 129<br />
8. Considerations Related to the Practical<br />
Performance of the Assessment of <strong>Drug</strong><br />
Sensitivity in Plasmodium falciparum •••••. 135